Valuation dashboard for Agenus Inc. (AGEN) with P/E 2.68, P/B -1.51, EV/EBITDA 2.34 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies.
Analysis Summary
Agenus Inc. reported revenue of $114.2M in the most recent fiscal year, growing at a 5-year CAGR of 5.3%.
Trailing-twelve-month margins: gross margin 75.6%, operating margin 27.3%, net margin 69.3%.
At the current price of $7.21, AGEN trades at a P/E of 2.68 and an ROE of -38.12%. Market capitalisation stands at $300M.
Balance sheet quality for AGEN: current ratio of 0.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 2.68 |
| Price / Book | -1.51 |
| EV / EBITDA | 2.34 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-23.99 |
| vs Current Price | -432.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AGEN | Agenus Inc. | $300M | 2.68 | -38.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $7.21 |
| Market Cap | $300M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -38.12% |
| Return on Invested Capital | -129.48% |
| Return on Assets | 53.28% |
| Gross Margin | 75.63% |
| Operating Margin | 27.28% |
| Net Margin | 69.34% |
Related companies: ABOS · FATE · HURA · INO · IRD · PLRX · SEER
Explore sector: Healthcare · Biotechnology
More sections of AGEN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks